Associated Papers
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
40359938 (PubMed )
Supplement: mmc3.xlsx › All
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
39688960 (PubMed )
Supplement: elife-99340-supp1.xlsx › CDN.Missense.gnomad
Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma.
Bresadola L et al.
Bjc Reports, 2024
39516649 (PubMed )
Supplement: 44276_2024_91_MOESM1_ESM.xlsx › Table_S4
Attribution of Cancer Origins to Endogenous, Exogenous, and Preventable Mutational Processes.
Cannataro VL et al.
Molecular Biology and Evolution, 2022
Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
Nakamura IT et al.
Cancer Science, 2021
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ et al.
Genome Medicine, 2020
32988402 (PubMed )
Supplement: 13073_2020_781_MOESM2_ESM.xlsx › 112_Potenti_APO-associ_panCa
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology.
Li Y et al.
Trends in Biochemical Sciences, 2019
Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor.
Zhang X et al.
Cancer Discovery, 2018
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
28775315 (PubMed )
Supplement: 41467_2017_289_MOESM7_ESM.xlsx › mutation_data
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Pan CX et al.
Plos One, 2015
26270481 (PubMed )
Supplement: pone.0134346.s006.xlsx › Supp_Table_3
Select a paper to view details